Assembled Chaos Podcast: Recent Episodes
Scott Wagers
The Assembled Chaos podcast is where we deconstruct the process of working in highly interactive consortia to derive principles and best practices for ambitious projects in the life sciences. It is also where we bring together though leaders to have a dialogue on emerging topics and challenges in the life sciences with the aim of understanding different perspectives and converging on possible solution.
Host: Scott Wagers, BioSci Consulting
Today, it's going to be a bit different. I have the honor of interviewing Matthew Wahlrab, who I simply just met by connecting through LinkedIn and we had a very interesting conversation. So I thought it would be nice to bring him here, to have some discussions. Matthew has started his own company. He is the CEO and founder of Innovative Foundations and he'll get into a bit more about what he does, but the key thing is, it's about looking at intellectual property strategies in companies. And one of the interesting things I wanted to bring him here for is that his focus is not just on medical stuff, it is somewhat medical, but also other industries. So, I think that is a different perspective. He has some very interesting insights on open innovation and what that is.
Podcast interview with Ulrike Koehl (Fraunhofer IZI), the coordinator or one of the co-coordinators of the Immune Safety Avatar project (imSAVAR).
In this podcast I interview the three co-coordinators of the U-BIOPRED project: Ian Adcock, Sven-Erik Dahlen, and Shamsah Kazani.
I have been working with the SHIELD consortium now for a little over 1.5 year now. The coordinator of SHIELD, David Dockrell, is in my mind the perfect example of a translational researcher who is working at the intersection of basic science and clinical medicine. He is able to bring together big concepts that have the potential to really make a difference and at the same lead a team that is delivering the meticulous and sometimes tedious basic science.
Working to help moderate the interactions as I do in SHIELD has been an interesting experience that has stretched my mind. Just the number of acronyms that fly around in the dialogue is mind boggling. That said, what I have learned is that the work that was conceived and is now being conducted in SHIELD is very elegant and illustrates what I think the future of medicine will look like. So, I asked, and David agreed to let me interview him.